Fluorescence In Situ Hybridization (FISH)

Turnaround Time: 3-5 days



Acupath Laboratories utilizes the FDA cleared FISH probes from Abbott Molecular to detect for chromosome aneuploidy as well as chromosome loss (UroVysion®) in patients with known Bladder Cancer. The UroVysion® assay is designed to detect these abnormalities in patients with recurring Bladder Cancer, and is a useful test for detecting Bladder Cancer in patients with persistent microcytic hematuria. Used in conjunction with urine cytology and cytstoscopy, the UroVysion® assay produces a 97% sensitive rate of detection of recurrent Bladder Cancer.

Barrett’s Esophagus FISH

The Acupath Barrett’s esophagus FISH assay utilizes esophageal brushings, collected in conjunction with biopsies, to identify genetic abnormalities that enable the clinician to risk stratify patients into high and low risk groups. The test provides invaluable, objective information to use when determining the aggressiveness of treatment and addresses several important deficiencies of current biopsy methodology including sampling error, the time required to collect the recommended # of biopsies, and inter-observer variability.

A 2016 Mayo Clinic retrospective cohort study demonstrates that, “patients with a polysomic FISH result had a significantly higher risk of developing EA within 2 years (14.2%} compared with patients with a non-polysomic FISH result”.

Prostate FISH (PTEN ERG)

Acupath Laboratories Acuprobe™ Prostate FISH panel consists of both the PTEN and ERG FISH probes. The PTEN (phosphatase and tensin) gene encodes for a known phosphatase blocking signaling pathways and has been identified to be involved in the regulation of DNA repair and genomic instability. Numerous studies have recognized that the loss of PTEN in prostate cancer to be an aggressive tumor (Yoshimoto et al (2007).

The ERG Acuprobe™ FISH locus is designed to detect ERG rearrangements with known fusion partners (TMPRSS2), as well as identify rearrangements with unknown fusion partners. Used in combination with AcuProbe™ PTEN FISH helps to provide prognostic information to clinicians for patients with prostate adenocarcinoma.


Gains of the long arm of chromosome 3 (TERC) have been observed in intraepithelial cells from both the cervix and anus in patients with high grade HPV viral infections. Acupath Acuprobe™ TERC FISH provides reliable results to determine TERC gene amplification in liquid based cytology specimens. The detection of TERC amplification in these patients can be an initial indicator that dysplasia may occur in these cells.


Acupath Laboratories utilizes the FDA cleared FISH probes from Abbott Molecular to detect HER2/neu amplification (PathVysion®). Utilized in combination with IHC staining and biopsy review, the PathVysion kit provides information on companion diagnostic responsiveness and used to predict disease-free and overall survival in stage II, node-positive breast cancer patients. Results of the FISH testing for HER2/neu amplification should not be the only factor when considering treatment of patients with stage II, node-positive breast cancer.

Melanoma FISH

The Acupath Laboratories Acuprobe™ Melanoma FISH panel is a combination of four individual probes that can help distinguish skin biopsies that are melanocytic lesions verses a benign nevus. Many specimens are difficult to assess with routine biopsy and IHC methodologies, and the additional genetic information gained from FISH allows for the detection of genetic changes that may indicative of melanoma.

The New Acupath
Reinvented, Reimagined, Rediscovered


CONTACT USQuestions?

    Name (required)*

    Email (required)*

    Phone Number (required)*